VIR$11.303.83%-0.45
After Hours: 11.66+0.36 +3.19%
Vir Biotechnology Inc (VIR)
Date: 2026-10-30 16:00O: 11.63H: 11.84L: 11.18C: 11.30Vol: 1.267M
Vir Biotechnology Inc stock is traded at $11.30, with a volume of 1,267,198. It is down -3.83% in the last 24 hours and up +1.07% over the past month. Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Previous Close:
$11.75
Open:
$11.63
24h Volume:
1,267,198
Relative Volume:
0.89
Market Cap:
$1.91B
Revenue:
$68.56M
Net Income/Loss:
-$437.99M
P/E Ratio:
-
EPS:
-$3.16
Net Cash Flow:
-$396.61M
1W Performance:
+6.91%
1M Performance:
+1.07%
6M Performance:
+10.62%
1Y Performance:
+90.56%
1-Day Range:
$11.18$11.84
1-Week Range:
$10.60$12.19
52-Week Range:
$4.82$12.19
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology IncSector
HealthcareIndustry
BiotechnologyPhone
415-906-4324Address
1800 OWENS STREET, SAN FRANCISCO, CA, USACompare VIR vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR Vir Biotechnology Inc | $11.30 | $1.91B | $68.56M | -$437.99M | -$396.61M | -$3.16 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
- O'Byrne JasonSep 09 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $11.13
- #Shares
- 28,333
- Value ($)
- 315,241
- #Shares Total
- 0
- O'Byrne JasonAug 25 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $10.48
- #Shares
- 23,148
- Value ($)
- 242,591
- #Shares Total
- 0
- O'Byrne JasonAug 24 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $9.90
- #Shares
- 14,352
- Value ($)
- 142,124
- #Shares Total
- 0
- O'Byrne JasonAug 21 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $9.81
- #Shares
- 25,000
- Value ($)
- 245,297
- #Shares Total
- 0
- Ramasastry SairaJun 29 '26Former Director
- Transaction
- Proposed Sale
- Cost
- $10.32
- #Shares
- 16,000
- Value ($)
- 165,139
- #Shares Total
- 0
- Napolitano JanetJun 01 '26Director
- Transaction
- Sale
- Cost
- $9.45
- #Shares
- 3,200
- Value ($)
- 30,240
- #Shares Total
- 21,216
- Sabatini BrentJun 01 '26SVP, Chief Accounting Officer
- Transaction
- Sale
- Cost
- $9.45
- #Shares
- 379
- Value ($)
- 3,582
- #Shares Total
- 61,902
- Sabatini BrentJun 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $9.45
- #Shares
- 379
- Value ($)
- 3,582
- #Shares Total
- 0
- Napolitano JanetJun 01 '26Director
- Transaction
- Proposed Sale
- Cost
- $9.45
- #Shares
- 3,200
- Value ($)
- 30,240
- #Shares Total
- 0
- SATO VICKI LMay 01 '26Director
- Transaction
- Sale
- Cost
- $10.05
- #Shares
- 22,000
- Value ($)
- 221,025
- #Shares Total
- 1,078,391
